Who are Nivolumab and rHuPH20's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nivolumab and Recombinant Human Hyaluronidase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nivolumab-and-rhuph20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Nivolumab and rHuPH20 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nivolumab and rHuPH20 (Nivolumab and rHuPH20) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor with hyaluronidase enzyme. Area: Oncology.

phase 3 PD-1 inhibitor with hyaluronidase enzyme PD-1; hyaluronic acid (via hyaluronidase) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Nivolumab and rHuPH20 (Nivolumab and rHuPH20) — Bristol-Myers Squibb. Nivolumab blocks PD-1 on immune cells to restore anti-tumor immunity, while rHuPH20 (recombinant human hyaluronidase) enhances drug penetration into tumors by degrading the hyaluronic acid-rich extracellular matrix.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nivolumab and rHuPH20 TARGET	Nivolumab and rHuPH20	Bristol-Myers Squibb	phase 3	PD-1 inhibitor with hyaluronidase enzyme	PD-1; hyaluronic acid (via hyaluronidase)
Nivolumab and Recombinant Human Hyaluronidase	Nivolumab and Recombinant Human Hyaluronidase	SWOG Cancer Research Network	phase 3	PD-1 inhibitor with hyaluronidase enzyme	PD-1; hyaluronic acid (via hyaluronidase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor with hyaluronidase enzyme class)

Bristol-Myers Squibb · 1 drug in this class
SWOG Cancer Research Network · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nivolumab and rHuPH20 — Competitive Intelligence Brief. https://druglandscape.com/ci/nivolumab-and-rhuph20. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab